Table 2. Details of Methotrexate Drug Use.
| Variable | Value (n=10) |
|---|---|
| Age at initiation of MTX (yr) | 52.3±9.7 |
| Disease duration at initiation of MTX (yr) | 6.7±5.5 |
| Initial administration route | |
| Parenteral | 2 (20.0) |
| Oral | 8 (80.0) |
| MTX dose (mg/wk) | 13.0±3.3 |
| MTX regimen | |
| MTX monotherapy | 4 (40.0) |
| MTX with anti-TNF-α | 6 (60.0) |
| Concomitant medication | |
| 5-ASA | 9 (90.0) |
| Colchicine | 4 (40.0) |
| Corticosteroid | 9 (90.0) |
| Anti-TNF-α | |
| Infliximab | 0 |
| Adalimumab | 6 (60.0) |
| Opioid | 3 (30.0) |
| NSAID | 6 (60.0) |
| Antibiotics | 4 (40.0) |
| Indication for MTX | |
| Thiopurine intolerance | 1 (10.0) |
| Thiopurine ineffectiveness | 0 |
| Failure of monotherapy anti-TNF-α | 6 (60.0) |
| Corticosteroid dependence | 3 (30.0) |
| Reason discontinue (n=4) | |
| Clinical ineffectiveness | 3 (75.0) |
| Self-interruption | 1 (25.0) |
Values are presented as mean±SD or number (%).
MTX, methotrexate; TNF, tumor necrosis factor; ASA, aminosalicylic acid.